Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Large Decline in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 23,500 shares, a drop of 61.9% from the February 28th total of 61,700 shares. Based on an average trading volume of 239,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.6% of the company’s shares are sold short.

Revelation Biosciences Stock Up 1.4 %

NASDAQ:REVB traded up $0.04 on Friday, reaching $2.80. The company’s stock had a trading volume of 1,706 shares, compared to its average volume of 113,264. Revelation Biosciences has a 12-month low of $2.36 and a 12-month high of $60.80. The stock has a 50 day moving average price of $3.92 and a 200 day moving average price of $8.66. The firm has a market cap of $2.53 million, a price-to-earnings ratio of -0.01 and a beta of 0.17.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.